Authorized Generics Benefit Consumers: Report
Analysis Group on Tuesday released a report that found that a surge in authorized generic entry has not contributed to delays in the timing of entry and has instead benefited consumers through lower drug prices.
“The rate of paragraph IV certifications is higher than it has ever been,” the report stated. “Sufficient incentives remain so...
To view the full article, register now.